CPhI Worldwide, organized by UBM (part of Informa PLC), has announced the finalists of the eagerly anticipated 2018 CPhI Pharma Awards.
This year’s edition features a record breaking number of entries, with over 250 from 174 participating companies across 17 categories, commending the innovations, technologies, and strategies driving pharma forward.
Such was the high caliber of entrants, 139 have been shortlisted, with the winners due to be announced during a live awards ceremony taking place at the luxurious Eurostars Madrid Tower Hotel on Tuesday October 9 – the opening day of CPhI Worldwide.
Innovations across flow chemistry, single-use technologies, drug delivery devices, contract services and packaging were amongst many shortlisted, with the judges concluding this was by far the highest ever standard of entries – further cementing 2018 as the year of innovation in pharma.
The awards for “Pharma company of the year”and “CEO of the year” will again be keenly sought as over 45,000 senior executives and 2500 companies attend at this year’s CPhI Worldwide.
To see the complete list of finalists, please visit https://awards.cphi.com/finalists/. The awards will be presented at the CPhI Awards Gala with over 350 guests in attendance.
To reserve a table for the CPhI Pharma Awards Gala, please visit https://awards.cphi.com/attend-the-gala/.
Beyond the Birthrate: The Societal Costs of Maternal Mortality
September 6th 2024Head of Medical Affairs and Outcomes Research at Organon, Charlotte Owens, MD, FACOG, discusses the most critical changes needed to close the gaps in R&D for maternal health solutions and how feasible they are to make.
Efsitora Demonstrates Non-Inferiority vs. Insulin Glargine, Degludec for Type 2 Diabetes
September 5th 2024Results from the QWINT-1 and QWINT-3 trials found that insulin-naïve patients achieved similar reductions in A1C levels using once-weekly efsitora compared to daily insulin glargine and degludec.